Chavers B M, Kim E M, Matas A J, Gillingham K J, Najarian J S, Mauer S M
Department of Pediatrics, University of Minnesota, Minneapolis 55455.
Pediatr Nephrol. 1994 Feb;8(1):57-61. doi: 10.1007/BF00868263.
At our institution, 521 kidney transplants were performed in 429 children (mean age 8.7 +/- 5.6-years) between 1969 and 1991. Of these transplants, 408 were primary, 113 were retransplants, 347 were living related, 171 were cadaver, and 3 were living nonrelated. Immunosuppression consisted of prednisone, azathioprine, and Minnesota antilymphocyte globulin (non-CSA) in 339 patients, total lymphoid irradiation in 8, and, more recently, cyclosporine (CSA) in addition in 168 patients. Average follow-up was 8.8 +/- 6.0 years. Actuarial graft survival in the non-CSA versus CSA groups at 1 year was 77.0% versus 85.7%; at 5 years, 59.6% versus 71.9%. Of 136 non-CSA patients, causes of graft loss at 5 years included: chronic rejection in 55 (40.4%), acute rejection in 27 (19.9%), recurrent disease in 16 (11.8%), technical complications in 8 (5.9%), infectious complications in 4 (2.9%), other causes in 5 (3.7%), and death with a functioning graft in 21 (15.4%). Of 40 CSA patients, causes of graft loss at 5 years included: chronic rejection in 16 (40.0%), acute rejection in 8 (20.0%), recurrent disease in 6 (15.0%), technical complications in 3 (7.5%), other causes in 2 (5.0%), and death with a functioning graft in 5 (12.5%). The causes of graft loss did not significantly differ in the non-CSA and CSA groups. Chronic rejection was the most common cause of graft loss in both groups. Research focusing on chronic rejection is needed to improve graft outcome in pediatric kidney transplantation.
1969年至1991年间,在我们机构为429名儿童(平均年龄8.7±5.6岁)实施了521例肾移植手术。这些移植手术中,408例为初次移植,113例为再次移植,347例为亲属活体供肾移植,171例为尸体供肾移植,3例为非亲属活体供肾移植。339例患者的免疫抑制方案包括泼尼松、硫唑嘌呤和明尼苏达抗淋巴细胞球蛋白(非环孢素A),8例采用全身淋巴照射,最近,168例患者在此基础上还加用了环孢素A(CSA)。平均随访时间为8.8±6.0年。非CSA组与CSA组1年时的移植肾 actuarial 生存率分别为77.0%和85.7%;5年时分别为59.6%和71.9%。136例非CSA患者中,5年时移植肾丢失的原因包括:慢性排斥反应55例(40.4%),急性排斥反应27例(19.9%),疾病复发16例(11.8%),技术并发症8例(5.9%),感染并发症4例(2.9%),其他原因5例(3.7%),移植肾有功能时死亡21例(15.4%)。40例CSA患者中,5年时移植肾丢失的原因包括:慢性排斥反应16例(40.0%),急性排斥反应8例(20.0%),疾病复发6例(15.0%),技术并发症3例(7.5%),其他原因2例(5.0%),移植肾有功能时死亡5例(12.5%)。非CSA组和CSA组移植肾丢失的原因无显著差异。慢性排斥反应是两组移植肾丢失的最常见原因。需要开展针对慢性排斥反应的研究以改善小儿肾移植的移植肾结局。 (注:“actuarial”直译为“精算的”,在医学语境中可能较难理解其确切含义,这里保留英文未翻译,可能需要结合更专业的医学知识进一步明确其在该文中的意义。)